Thermo Fisher Scientific Inc. (0R0H.L)
USD 428.58
(1.97%)
USD 428.58
(1.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.99 Billion USD | -13.74% |
| 2022 | 6.95 Billion USD | -10.03% |
| 2021 | 7.72 Billion USD | 21.18% |
| 2020 | 6.37 Billion USD | 72.48% |
| 2019 | 3.69 Billion USD | 25.8% |
| 2018 | 2.93 Billion USD | 32.04% |
| 2017 | 2.22 Billion USD | 10.05% |
| 2016 | 2.02 Billion USD | 2.35% |
| 2015 | 1.97 Billion USD | 4.28% |
| 2014 | 1.89 Billion USD | 48.78% |
| 2013 | 1.27 Billion USD | 8.1% |
| 2012 | 1.17 Billion USD | -11.43% |
| 2011 | 1.32 Billion USD | 28.42% |
| 2010 | 1.03 Billion USD | 21.79% |
| 2009 | 850.3 Million USD | -14.47% |
| 2008 | 994.2 Million USD | 30.63% |
| 2007 | 761.1 Million USD | 350.53% |
| 2006 | 168.93 Million USD | -24.32% |
| 2005 | 223.21 Million USD | -38.31% |
| 2004 | 361.83 Million USD | 80.91% |
| 2003 | 200 Million USD | -35.42% |
| 2002 | 309.73 Million USD | 39758.13% |
| 2001 | -781 Thousand USD | 97.84% |
| 2000 | -36.11 Million USD | 79.32% |
| 1999 | -174.6 Million USD | -195.99% |
| 1998 | 181.9 Million USD | -23.99% |
| 1997 | 239.3 Million USD | 25.42% |
| 1996 | 190.8 Million USD | 36.19% |
| 1995 | 140.1 Million USD | 35.49% |
| 1994 | 103.4 Million USD | 34.99% |
| 1993 | 76.6 Million USD | 29.39% |
| 1992 | 59.2 Million USD | 25.69% |
| 1991 | 47.1 Million USD | 38.94% |
| 1990 | 33.9 Million USD | 37.8% |
| 1989 | 24.6 Million USD | 22.39% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.32 Billion USD | -18.53% |
| 2024 Q3 | 1.63 Billion USD | 5.3% |
| 2024 Q2 | 1.54 Billion USD | 16.57% |
| 2023 Q2 | 1.36 Billion USD | 5.59% |
| 2023 Q3 | 1.71 Billion USD | 26.01% |
| 2023 Q4 | 1.63 Billion USD | -4.96% |
| 2023 FY | 5.99 Billion USD | -13.74% |
| 2023 Q1 | 1.28 Billion USD | -18.21% |
| 2022 Q4 | 1.57 Billion USD | 5.42% |
| 2022 Q1 | 2.21 Billion USD | 33.59% |
| 2022 Q2 | 1.66 Billion USD | -24.88% |
| 2022 FY | 6.95 Billion USD | -10.03% |
| 2022 Q3 | 1.49 Billion USD | -10.16% |
| 2021 FY | 7.72 Billion USD | 21.18% |
| 2021 Q1 | 2.33 Billion USD | -6.45% |
| 2021 Q2 | 1.82 Billion USD | -21.78% |
| 2021 Q3 | 1.9 Billion USD | 4.05% |
| 2021 Q4 | 1.65 Billion USD | -12.83% |
| 2020 Q1 | 788 Million USD | -21.36% |
| 2020 Q4 | 2.49 Billion USD | 29.23% |
| 2020 Q2 | 1.15 Billion USD | 46.7% |
| 2020 FY | 6.37 Billion USD | 72.48% |
| 2020 Q3 | 1.93 Billion USD | 67.21% |
| 2019 Q1 | 815 Million USD | -9.24% |
| 2019 Q2 | 1.11 Billion USD | 37.3% |
| 2019 Q3 | 760 Million USD | -32.08% |
| 2019 Q4 | 1 Billion USD | 31.84% |
| 2019 FY | 3.69 Billion USD | 25.8% |
| 2018 Q1 | 579 Million USD | 9.64% |
| 2018 Q4 | 898 Million USD | 26.66% |
| 2018 FY | 2.93 Billion USD | 32.04% |
| 2018 Q3 | 709 Million USD | -5.72% |
| 2018 Q2 | 752 Million USD | 29.88% |
| 2017 Q3 | 534 Million USD | -12.75% |
| 2017 Q1 | 551 Million USD | -12.47% |
| 2017 Q2 | 612 Million USD | 11.07% |
| 2017 Q4 | 528.1 Million USD | -1.1% |
| 2017 FY | 2.22 Billion USD | 10.05% |
| 2016 FY | 2.02 Billion USD | 2.35% |
| 2016 Q1 | 402.2 Million USD | -33.26% |
| 2016 Q3 | 473.5 Million USD | -8.34% |
| 2016 Q4 | 629.5 Million USD | 32.95% |
| 2016 Q2 | 516.6 Million USD | 28.44% |
| 2015 FY | 1.97 Billion USD | 4.28% |
| 2015 Q1 | 385.1 Million USD | -35.94% |
| 2015 Q2 | 511.6 Million USD | 32.85% |
| 2015 Q3 | 476.1 Million USD | -6.94% |
| 2015 Q4 | 602.6 Million USD | 26.57% |
| 2014 Q4 | 601.2 Million USD | 27.48% |
| 2014 Q1 | 543.1 Million USD | 58.75% |
| 2014 Q2 | 278.5 Million USD | -48.72% |
| 2014 Q3 | 471.6 Million USD | 69.34% |
| 2014 FY | 1.89 Billion USD | 48.78% |
| 2013 Q2 | 277.4 Million USD | -17.49% |
| 2013 Q1 | 336.2 Million USD | -10.68% |
| 2013 FY | 1.27 Billion USD | 8.1% |
| 2013 Q4 | 342.1 Million USD | 7.71% |
| 2013 Q3 | 317.6 Million USD | 14.49% |
| 2012 Q3 | 290.4 Million USD | 24.21% |
| 2012 Q2 | 233.8 Million USD | -15.69% |
| 2012 Q1 | 277.3 Million USD | -4.02% |
| 2012 FY | 1.17 Billion USD | -11.43% |
| 2012 Q4 | 376.4 Million USD | 29.61% |
| 2011 Q4 | 288.9 Million USD | 8.85% |
| 2011 Q1 | 252.2 Million USD | -15.23% |
| 2011 Q2 | 523.4 Million USD | 107.53% |
| 2011 Q3 | 265.4 Million USD | -49.29% |
| 2011 FY | 1.32 Billion USD | 28.42% |
| 2010 FY | 1.03 Billion USD | 21.79% |
| 2010 Q4 | 297.5 Million USD | 10.8% |
| 2010 Q3 | 268.5 Million USD | 13.15% |
| 2010 Q2 | 237.3 Million USD | 2.15% |
| 2010 Q1 | 232.3 Million USD | -15.0% |
| 2009 Q4 | 273.3 Million USD | 23.55% |
| 2009 FY | 850.3 Million USD | -14.47% |
| 2009 Q2 | 206.9 Million USD | 38.95% |
| 2009 Q3 | 221.2 Million USD | 6.91% |
| 2009 Q1 | 148.9 Million USD | -48.69% |
| 2008 Q4 | 290.2 Million USD | 33.06% |
| 2008 FY | 994.2 Million USD | 30.63% |
| 2008 Q1 | 233 Million USD | -2.84% |
| 2008 Q2 | 249.5 Million USD | 7.08% |
| 2008 Q3 | 218.1 Million USD | -12.59% |
| 2007 Q1 | 138.9 Million USD | 448.66% |
| 2007 Q4 | 239.8 Million USD | 9.75% |
| 2007 FY | 761.1 Million USD | 350.53% |
| 2007 Q2 | 163.9 Million USD | 18.0% |
| 2007 Q3 | 218.5 Million USD | 33.31% |
| 2006 FY | 168.93 Million USD | -24.32% |
| 2006 Q1 | 46.9 Million USD | -16.85% |
| 2006 Q3 | 48.8 Million USD | 1.92% |
| 2006 Q4 | 25.31 Million USD | -48.12% |
| 2006 Q2 | 47.88 Million USD | 2.09% |
| 2005 Q4 | 56.4 Million USD | -2.3% |
| 2005 FY | 223.21 Million USD | -38.31% |
| 2005 Q3 | 57.73 Million USD | -4.13% |
| 2005 Q2 | 60.22 Million USD | 23.27% |
| 2005 Q1 | 48.85 Million USD | -59.66% |
| 2004 Q3 | 107.47 Million USD | 18.0% |
| 2004 Q1 | 43.12 Million USD | -30.37% |
| 2004 FY | 361.83 Million USD | 80.91% |
| 2004 Q4 | 121.09 Million USD | 12.68% |
| 2004 Q2 | 91.08 Million USD | 111.21% |
| 2003 Q2 | 53.13 Million USD | 45.88% |
| 2003 Q3 | 48.51 Million USD | -8.7% |
| 2003 Q4 | 61.92 Million USD | 27.65% |
| 2003 Q1 | 36.42 Million USD | -58.2% |
| 2003 FY | 200 Million USD | -35.42% |
| 2002 FY | 309.73 Million USD | 39758.13% |
| 2002 Q3 | 39.01 Million USD | -43.06% |
| 2002 Q2 | 68.51 Million USD | -40.44% |
| 2002 Q1 | 115.04 Million USD | 1775.07% |
| 2002 Q4 | 87.15 Million USD | 123.37% |
| 2001 Q4 | -6.86 Million USD | -126.13% |
| 2001 FY | -781 Thousand USD | 97.84% |
| 2001 Q3 | 26.27 Million USD | 5.19% |
| 2001 Q2 | 24.98 Million USD | 155.3% |
| 2001 Q1 | -45.17 Million USD | 50.18% |
| 2000 Q4 | -90.68 Million USD | -838.52% |
| 2000 FY | -36.11 Million USD | 79.32% |
| 2000 Q3 | 12.27 Million USD | -49.38% |
| 2000 Q1 | 15.82 Million USD | 495.58% |
| 2000 Q2 | 24.25 Million USD | 53.29% |
| 1999 Q2 | -235.2 Million USD | -931.12% |
| 1999 FY | -174.6 Million USD | -195.99% |
| 1999 Q1 | 28.29 Million USD | -23.52% |
| 1999 Q4 | -4 Million USD | -111.01% |
| 1999 Q3 | 36.32 Million USD | 115.45% |
| 1998 FY | 181.9 Million USD | -23.99% |
| 1998 Q1 | 65.5 Million USD | -5.35% |
| 1998 Q2 | 61.8 Million USD | -5.65% |
| 1998 Q3 | 17.6 Million USD | -71.52% |
| 1998 Q4 | 37 Million USD | 110.23% |
| 1997 FY | 239.3 Million USD | 25.42% |
| 1997 Q4 | 69.2 Million USD | 11.79% |
| 1997 Q3 | 61.9 Million USD | 10.14% |
| 1997 Q2 | 56.2 Million USD | 7.87% |
| 1997 Q1 | 52.1 Million USD | -2.8% |
| 1996 FY | 190.8 Million USD | 36.19% |
| 1996 Q1 | 41 Million USD | 3.02% |
| 1996 Q4 | 53.6 Million USD | 4.69% |
| 1996 Q2 | 44.9 Million USD | 9.51% |
| 1996 Q3 | 51.2 Million USD | 14.03% |
| 1995 Q2 | 32.6 Million USD | 10.51% |
| 1995 Q4 | 39.8 Million USD | 4.46% |
| 1995 Q3 | 38.1 Million USD | 16.87% |
| 1995 Q1 | 29.5 Million USD | 1.72% |
| 1995 FY | 140.1 Million USD | 35.49% |
| 1994 Q2 | 24.2 Million USD | 7.56% |
| 1994 Q3 | 27.7 Million USD | 14.46% |
| 1994 Q4 | 29 Million USD | 4.69% |
| 1994 FY | 103.4 Million USD | 34.99% |
| 1994 Q1 | 22.5 Million USD | -0.44% |
| 1993 Q2 | 17.6 Million USD | 14.29% |
| 1993 Q4 | 22.6 Million USD | 8.13% |
| 1993 Q1 | 15.4 Million USD | -9.94% |
| 1993 Q3 | 20.9 Million USD | 18.75% |
| 1993 FY | 76.6 Million USD | 29.39% |
| 1992 Q3 | 15.5 Million USD | 11.51% |
| 1992 Q4 | 17.1 Million USD | 10.32% |
| 1992 Q1 | 12.6 Million USD | -11.27% |
| 1992 Q2 | 13.9 Million USD | 10.32% |
| 1992 FY | 59.2 Million USD | 25.69% |
| 1991 Q3 | 13.6 Million USD | 33.33% |
| 1991 Q4 | 14.2 Million USD | 4.41% |
| 1991 Q1 | 8.2 Million USD | -17.17% |
| 1991 FY | 47.1 Million USD | 38.94% |
| 1991 Q2 | 10.2 Million USD | 24.39% |
| 1990 Q3 | 9.5 Million USD | 17.28% |
| 1990 Q4 | 9.9 Million USD | 4.21% |
| 1990 Q1 | 6 Million USD | -21.05% |
| 1990 Q2 | 8.1 Million USD | 35.0% |
| 1990 FY | 33.9 Million USD | 37.8% |
| 1989 Q1 | - USD | 0.0% |
| 1989 FY | 24.6 Million USD | 22.39% |
| 1989 Q4 | 7.6 Million USD | 15.15% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q3 | 6.6 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 2043.412% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 1802.699% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 4054.903% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 2271.11% |
| bluebird bio, Inc. | -211.91 Million USD | 2928.991% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 5158.517% |
| Imunon, Inc. | -19.51 Million USD | 30819.995% |
| Editas Medicine, Inc. | -153.21 Million USD | 4012.7% |
| IQVIA Holdings Inc. | 1.35 Billion USD | -341.458% |
| Mettler-Toledo International Inc. | 788.77 Million USD | -660.036% |
| Myriad Genetics, Inc. | -112 Million USD | 5452.679% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -2300.881% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -455447.112% |
| Verastem, Inc. | -87.36 Million USD | 6961.859% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 169.419% |
| Waters Corporation | 642.23 Million USD | -833.46% |
| Biogen Inc. | 1.16 Billion USD | -416.321% |
| Nektar Therapeutics | -276.05 Million USD | 2271.661% |
| Perrigo Company plc | -12.7 Million USD | 47304.724% |
| Dynavax Technologies Corporation | -6.38 Million USD | 93933.151% |
| Illumina, Inc. | -1.16 Billion USD | 616.365% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 13540.705% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 1450.113% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 5522.444% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 15140.14% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -3476.009% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 2425.166% |
| Evolus, Inc. | -61.68 Million USD | 9818.732% |
| Adicet Bio, Inc. | -142.65 Million USD | 4302.358% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 6875.466% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | -51.634% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 2965.021% |
| FibroGen, Inc. | -284.23 Million USD | 2209.192% |
| Agilent Technologies, Inc. | 1.24 Billion USD | -383.468% |
| OPKO Health, Inc. | -188.86 Million USD | 3274.259% |
| Homology Medicines, Inc. | -53.74 Million USD | 11254.941% |
| Geron Corporation | -184.12 Million USD | 3355.905% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 1461.751% |
| Exelixis, Inc. | 207.76 Million USD | -2785.472% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 7079.452% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 12719.724% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 1345.864% |
| Zoetis Inc. | 2.34 Billion USD | -155.759% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 2605.873% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 11163.335% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | -65.626% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 14306.498% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 1736.699% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 1218.518% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -5548.2% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -2028.952% |
| Blueprint Medicines Corporation | -506.98 Million USD | 1282.483% |
| Insmed Incorporated | -749.56 Million USD | 899.795% |
| TG Therapeutics, Inc. | 12.67 Million USD | -47209.028% |
| Incyte Corporation | 597.59 Million USD | -903.181% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 888.297% |